NCT01583530 - Study of Belimumab Administered Subcutaneously to Healthy Subjects | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Healthy

Interventions

BIOLOGICAL

Single Dose Group: Belimumab IV 240 mg

Belimumab IV 240 mg administered on Day 0

BIOLOGICAL

Single Dose Group: Belimumab SC 2 x 120 mg

Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0

BIOLOGICAL

Single Dose Group: Belimumab SC 1 x 240 mg

Belimumab SC 240 mg x 1 injection on Day 0

BIOLOGICAL

Single Dose Group: Belimumab SC 1 x 200 mg

Belimumab SC 200 mg x 1 injection on Day 0

BIOLOGICAL

Multiple Dose Group: Belimumab SC 2 x 120 mg weekly

Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21

BIOLOGICAL

Multiple Dose Group: Belimumab SC 1 x 200 mg weekly

Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21

Trial Locations (4)

Daytona Beach

Evansville

Dallas

Madison